Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis. Issue 1 (12th July 2016)

• Record Type: Journal Article
• Authors: Jendrek, Sebastian Torben; Gotthardt, Daniel; Nitzsche, Thomas; Widmann, Laila; Korf, Tobias; Michaels, Maike Anna; Weiss, Karl-Heinz; Liaskou, Evaggelia; Vesterhus, Mette; Karlsen, Tom Hemming; Mindorf, Swantje; Schemmer, Peter; Bär, Florian; Teegen, Bianca; Schröder, Torsten; Ehlers, Marc; Hammers, Christoph Matthias; Komorowski, Lars; Lehnert, Hendrik; Fellermann, Klaus; Derer, Stefanie; Hov, Johannes Roksund; Sina, Christian
• Is Part Of: Gut. Volume 66:Issue 1(2017)
• Page Start: 137
• Page End: 144
• Publication Date: 2016-07-12
• Subjects: PRIMARY SCLEROSING CHOLANGITIS -- PANCREATIC ANTIBODIES -- CHOLANGIOCARCINOMA -- AUTO-ANTIBODIES -- INFLAMMATORY BOWEL DISEASE; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2016-311739
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: Pancreatic autoantibodies (PABs), comprising antibodies against glycoprotein 2 (anti-GP2), are typically associated with complicated phenotypes in Crohn's disease, but have also been observed with variable frequencies in patients with UC. In a previous study, we observed a high frequency of primary sclerosing cholangitis (PSC) in patients with anti-GP2-positive UC. We therefore aimed to characterise the role of anti-GP2 in PSC. Design: In an evaluation phase, sera from 138 well-characterised Norwegian patients with PSC were compared with healthy controls (n=52), and patients with UC without PSC (n=62) for the presence of PABs by indirect immunofluorescence. Further, 180 German patients with PSC served as a validation cohort together with 56 cases of cholangiocarcinoma without PSC, 20 of secondary sclerosing cholangitis (SSC) and 18 of autoimmune hepatitis. Results: Anti-GP2 IgA specifically occurred at considerable rates in large bile duct diseases (cholangiocarcinoma=36%, PSC and SSC about 50%). In PSC, anti-GP2 IgA consistently identified patients with poor survival during follow-up (Norwegian/German cohort: p Log Rank=0.016/0.018). Anti-GP2 IgA was associated with the development of cholangiocarcinoma in both PSC cohorts, yielding an overall OR of cholangiocarcinoma in patients with anti-GP2 IgA-positive PSC of 5.0 (p=0.001). Importantly, this association remained independent of disease duration, bilirubin level and age. Conclusions: Anti-GP2 IgA can be hypothesised as a novel marker in large bile duct diseases. In particular, in PSC, anti-GP2 IgA identified a subgroup of patients with severe phenotype and poor survival due to cholangiocarcinoma. Anti-GP2 IgA may therefore be a clinically valuable tool for risk stratification in PSC.